Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Am J Sports Med. 2019 Apr 17;47(6):1385–1395. doi: 10.1177/0363546519832864

Figure 7.

Figure 7.

Myostatin treatment induces proliferation of human skeletal muscle–derived fibroblasts. (A-D) Representative images of EdU-labeled fibroblasts following 12-hour VEH or MSTN (300 ng/mL) treatment. (E) Myostatin treatment results in a 70% increase in EdU+ fibroblast frequency. Values are presented as percentage EdU+/DAPI+, mean ± SD, n = 3, with isolates assessed in duplicate. *P < .05 vs VEH-treated group. Scale bar = 200 μm. DAPI, 4#,6-diamidino-2-phenylindole; EdU, 5-ethynyl-2′-deoxyuridine; VEH, vehicle.